Key result
Aortic Mitroflow bioprosthesis shows ~7% early mortality with 27% survival at 18 years.
Why the study?
A multicentre longitudinal evaluation of the Mitroflow pericardial bioprosthesis over 20 years was needed to assess long-term postoperative outcomes and valve-related events.
Population
1591 patients with Mitroflow aortic bioprosthesis from 12 centres
Design
Multicentre longitudinal cohort study
Follow-up
Median 61.9 months (IQR 30.8-90.9 months)
Loading...
Supports Mitroflow durability in patients >70 years; observational data leave comparative efficacy versus contemporary valves open.
Cohort (n=1,591)
Yes
The Mitroflow pericardial bioprosthesis provides favorable long-term outcomes with low rates of structural valve degeneration, particularly in patients older than 70 years.
A 2010 study conducted a cohort in Aortic valve replacement (n=1,591). Mitroflow pericardial bioprosthesis was evaluated on Early (30-day) mortality. Mitroflow pericardial bioprosthesis in the aortic position resulted in an early mortality of 6.5% and actuarial survival rates of 53%, 34%, and 27% at 10, 15, and 18 years, respectively.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: